Patients must have no known allergies to exemestane, entinostat, or medications that have a benzamide structure (e.g., tiapride, remoxipride, clebropride)
Known allergies to carfilzomib or Captisol
History of any drug allergies or significant adverse reactions to any of the components of SM-88.
Patients with known and documented allergies to any of the penicillins, cephalosporins, or beta-lactamase inhibitors
Known allergies to medical adhesives or hydrogel
Known allergies to medical adhesives or hydrogel
History of allergies to any active or inactive ingredients of atezolizumab.
Patients who cannot tolerate pneumocystis jirovecii pneumonia (PJP) prophylaxis (i.e., known Bactrim and pentamidine allergies)
Patients with known or suspected allergies to any component of the vaccine.
ALLERGIES AND ADVERSE DRUG REACTION
Known allergies to medical adhesives or hydrogel
Patients with known contrast allergies requiring pre-medication with steroids
Known allergies, hypersensitivity or intolerance to apalutamide, abiraterone acetate, prednisone, or GNRH agonist or GNRH antagonist
Subjects with three or more drug allergies from separate drug classes
History of multiple drug allergies or intolerance to subcutaneous injections
Subjects with three or more drug allergies from separate drug classes
Allergies, hypersensitivity, or intolerance to prednisone, LHRH analog or excipients of prednisone LHRH analog, abiraterone acetate and apalutamide.
Allergies to any vaccine, that after discussion with Immunovaccine, are serious enough to warrant exclusion from this study
Prior use of niclosamide or allergies to niclosamide
Allergies and adverse drug reaction
Allergies to Lidocaine or Novocain
Allergies to imaging dyes
Documented penicillin or cephalosporin allergies
Subjects with any underlying conditions, which would contraindicate therapy with, study treatment (or allergies to reagents used in this study)
Known allergies to any of the components of the investigational treatment regimen or required ancillary treatments
Patients with NSAIDs allergies, known lactose allergy, a history of recent gastrointestinal (GI) bleed (less than 2 weeks), and those who are on therapeutic dose anticoagulants will be excluded from this protocol
Patients with allergies to any component of the vaccine will be excluded from the protocol
Subjects must not have allergies to any compounds similar to CDB-4124
Allergies to lidocaine or marcaine
Allergies to imaging dyes
Known history of allergies or sensitivities to gentamicin.
Patients with allergies to isosulfan blue or technetium, which would preclude sentinel node mapping
Antibiotic allergies that would preclude treatment for a C. novyi-NT infection
Participants with known or suspected allergies to any component of the vaccine
Known allergies to clofarabine, melphalan, sirolimus or tacrolimus
Allergies or hypersensitivities to monoclonal antibodies, BMS-986012 or related compounds, including fucosyl-GM1 vaccine and Nivolumab
Subjects with any known severe allergies (e.g. anaphylaxis) to any active or inactive ingredients in the study drugs.
Known allergies, hypersensitivity, or intolerance to any form of heparin or azacitidine
No eating disorders, food allergies or intolerances
Any prior allergies to curcumin or turmeric
Known allergies to any of the components of the investigational treatment regimen or required ancillary treatments
Any history of allergies to grapes or grape seed
Known allergies, hypersensitivity or intolerance to abiraterone acetate, prednisone or degarelix
Subjects with any underlying conditions which would contraindicate therapy with study treatment (or allergies to reagents)
Subject has any underlying conditions, which would contraindicate therapy with study treatment (or allergies to reagents used in this study)
Antibiotic allergies that would preclude treatment for a C. novyi-NT infection.
Allergies to excipients in the study drug.
Hypersensitivities, allergies or contraindications to study medications; intolerance of medical tape or sticking plaster.
Allergies to temozolomide, dacarbazine, IgG containing agents
Allergies and Adverse Drug Reaction
Allergies to any component of the vaccine
Known allergies, hypersensitivity, or intolerance to dacarbazine does not apply
Allergies to eggs, lecithin or soy products.
No allergies to and not currently using varenicline
Significant food allergies which would make the subject unable to consume the food provided (soy or nut allergy)
Patients with known allergies to egg products, neomycin, or tetanus toxoid
Subjects with allergies to any supplements.
Patients with allergies to any of the ingredients in the nutritional supplement
Milk protein intolerance/allergies (lactose intolerance is acceptable)
Known allergies or intolerance to cisplatin and similar platinum-containing compounds
Allergic history, including anaphylaxis or severe allergies to products in study serum or placebo
Has known allergies or intolerance to brilacidin, cisplatin or carboplatin
Patients will be excluded from the trial if they have had a history of allergies or intolerance to fructooligosaccharides or the components of FOS including fructose and glucose
Known allergies or intolerance to cisplatin and similar platinum-containing compounds
Known allergies, hypersensitivity, or intolerance to any of the study medications.
Cutaneous photosensitivity to wavelengths of 400-450 nm, porphyria or known allergies to porphyrins
All patients who are have known allergies or are sensitive to silver and acrylic adhesives
Allergies to multiple food items or nutritional supplements
History of food allergies and/or major dietary restrictions
Subjects should not have known allergies to cruciferous vegetables
No known allergies to tree nuts (i.e. almonds)
Subjects with three or more drug allergies from separate drug classes
Subjects with three or more drug allergies from separate drug classes
No known allergies to contrast material
No known allergies to contrast material
Known allergies to contrast material
History of allergies to iodides
Subjects with a history of iodide allergies
Allergy to gadolinium or other severe drug allergies
Subjects with three or more drug allergies from separate drug classes
Patients with allergies to iodinated contrast not amenable to pre-medication
History of allergies and adverse drug reaction to study drug components
Subjects with three or more drug allergies from separate drug classes
Allergies to study medications, such as, lidocaine, Versed, or Cetacaine
Allergies and Adverse Drug Reaction a. Subjects with known hypersensitivity to excipients of Dasatinib tablets
